TissueGnostics is an industrial beneficiary of eRaDicate consortium

The eRaDicate project was launched to test novel nuclear-receptor targeting drugs as anti-cancer agents, such as the retinoic acid receptor (RAR) and the vitamin D receptor (VDR) using a variety of molecular biology methods. TissueGnostics is the official industry beneficiary of the project.